Bilal Arif - Sarepta Therapeutics Executive Officer

Bilal Arif Latest Insider Activity

Sarepta Therapeutics Management Efficiency

The company has return on total asset (ROA) of 0.0377 % which means that it generated a profit of $0.0377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1971 %, meaning that it created $0.1971 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.06 in 2025. Return On Capital Employed is likely to gain to 0.07 in 2025. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.2 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 46.7 M in 2025.

Similar Executives

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people. Sarepta Therapeutics (SRPT) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 1,372 people. Sarepta Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Sarepta Therapeutics Leadership Team

Sarepta Stock Performance Indicators

Additional Tools for Sarepta Stock Analysis